Description: Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Home Page: www.aurobindo.com
Galaxy, Plot No. 1
Hyderabad,
500032
India
Phone:
91 40 6672 5000
Officers
| Name | Title |
|---|---|
| Mr. Kambam Nithyananda Reddy | Vice Chairman & MD |
| Mr. Mettu Madan Mohan Reddy | Whole-Time Director |
| Dr. Makkapati Satakarni B.E., M.B.A., Ph.D. | President of Biologics, CEO of Biologics, Vaccines and Peptid & Director |
| Mr. Santhanam Subramanian | Chief Financial Officer |
| Dr. S. Vijaya Kumar | President of Technical |
| Mr. B. Adi Reddy | Compliance Officer & Company Secretary |
| Mr. G. P. Prasad | Senior Vice President of Global Finance & Operations |
| Dr. Sudhir Bimal Singhi | Head of Global Finance Operations |
| Dr. A. Rama Mohana Rao | Chief Quality Officer -Corporate QA |
| Dr. V. K. Handa | President of Chemical Research |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 8.3612 |
|---|---|
| Trailing PE: | 20.3262 |
| Price-to-Book MRQ: | 2.344 |
| Price-to-Sales TTM: | 2.3926 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 26015 |